Mutual Funds Sahi Hai!
To avail the service, you will be redirected to loans.geojitcredits.com
Lupin Ltd is down for a fifth straight session today. The stock is quoting at Rs 2104.3, down 0.02% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is down around 0.4% on the day, quoting at 23541.1. The Sensex is at 75140.89, down 0.58%.Lupin Ltd has lost around 8.51% in last one month.Meanwhile, Nifty Pharma index of which Lupin Ltd is a constituent, has increased around 0.92% in last one month and is currently quoting at 26880.8, down 0.59% on the day. The volume in the stock stood at 3.18 lakh shares today, compared to the daily average of 9.12 lakh shares in last one month.
The benchmark September futures contract for the stock is quoting at Rs 2110.5, up 0.24% on the day. Lupin Ltd jumped 6.29% in last one year as compared to a 5.73% slide in NIFTY and a 20.8% spurt in the Nifty Pharma index.
The PE of the stock is 14.58 based on TTM earnings ending June 26.
The U.S. FDA has approved Lupin's Modafinil Tablets USP, 100 mg and 200 mg as bioequivalent to the reference listed drug (RLD), Provigil® Tablets of Nuvo Pharmaceuticals (Ireland) DAC, and is indicated to improve wakefulness in adult patients with excessive sleepiness associated with narcolepsy, obstructive sleep apnea (OSA) or shift work disorder (SWD).
Modafinil Tablets (RLD Provigil®) had estimated annual sales of USD 70.7 million in the U.S. (IQVIA MAT Jul 2026).
In view of the above, the issued and paid-up share capital of the Company has increased to Rs 91,45,31,722 consisting of 45,72,65,861 equity shares of Rs 2/- each.
Visus Therapeutics Inc. is a wholly owned subsidiary of Tenpoint Therapeutics Holding,
This partnership provides VISUfarma the exclusive rights to undertake regulatory activities, commercialization, marketing, promotion, distribution and sale of YUVEZZI (carbachol and brimonidine tartrate ophthalmic solution), in the licensed territories.
YUVEZZI is a proprietary ophthalmic product indicated for the treatment of presbyopia in adults.
Under the agreement, VISUfarma will make a strategic investment in Visus. Tenpoint and Visus, individually or collectively, will also be eligible to receive regulatory and commercial milestone payments, as well as tiered royalties based on net sales.
Tenpoint is advancing commercialization of YUVEZZI in the United States following its recent U.S. FDA approval.
The aforementioned agreement further expands the reach of YUVEZZI through strategic regional partnerships worldwide, and Tenpoint has already submitted an MMA in the UK, via the MHRA’s International Recognition Procedure. It will continue to execute its plans for regulatory applications for YUVEZZI in other key regions worldwide.
Vinita Gupta, chief executive officer, Lupin, said: 'We are delighted to partner with Tenpoint Therapeutics to bring a novel ophthalmic therapy that advances our Specialty Care strategy.
Building on the strategic acquisition of VISUfarma, this partnership further strengthens our vision care franchise and expands our presence across key European markets.
The addition of YUVEZZI underscores our commitment to broadening access to differentiated therapies, improving patient outcomes, and reinforcing our leadership in eye care across the licensed territories.”
Lupin is a global pharmaceutical company focused on branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients across multiple therapeutic segments.
The company’s consolidated profit after tax stood at Rs 1,415 crore in Q1 FY27, up 16.08% from Rs 1,219.03 crore in Q1 FY26. Net sales rose 33.32% to Rs 8,217.23 crore in Q1 FY27 over Q1 FY26.
The scrip rose 0.04% to currently trade at Rs 2220.85 on the BSE.
The U.S. FDA has approved Lupin's Pitolisant Tablets, 4.45 mg and 17.8 mg, as bioequivalent to Wakix® for the indications in the approved labeling.
Lupin Ltd dropped for a fifth straight session today. The stock is quoting at Rs 2268.1, down 1.39% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is down around 0.54% on the day, quoting at 24450. The Sensex is at 78139.58, down 0.51%.Lupin Ltd has lost around 9.01% in last one month.Meanwhile, Nifty Pharma index of which Lupin Ltd is a constituent, has increased around 3.64% in last one month and is currently quoting at 26479.55, up 0.37% on the day. The volume in the stock stood at 7.94 lakh shares today, compared to the daily average of 11.47 lakh shares in last one month.
The benchmark August futures contract for the stock is quoting at Rs 2273, down 0.21% on the day. Lupin Ltd jumped 16.68% in last one year as compared to a 0.15% slide in NIFTY and a 22.17% spurt in the Nifty Pharma index.
The PE of the stock is 15.71 based on TTM earnings ending June 26.
Lupin announced that it has received approval from the U.S. Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Sodium Zirconium Cyclosilicate for Oral Suspension, 5 g/packet and 10 g/packet.
The U.S. FDA has approved Lupin's Sodium Zirconium Cyclosilicate for Oral Suspension, 5 g/packet and 10 g/packet as bioequivalent to the reference listed drug (RLD) Lokelma® for Oral Suspension of AstraZeneca Pharmaceuticals LP and is indicated for the treatment of hyperkalemia in adults.
Sodium Zirconium Cyclosilicate for Oral Suspension (RLD Lokelma®) had estimated annual sales of USD 568 million in the U.S. (IQVIA MAT Jun 2026).
Lupin announced that following approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application, the company launched Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vial in the United States.
Lupin's Sugammadex Injection is the bioequivalent to Bridion® Injection of Merck, Sharp & Dohme LLC (Merck) and is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults and pediatric patients aged 2 years and older undergoing surgery.
Lupin announced that it has received approval under the Federal Food, Drug, and Cosmetic Act (FD&C Act) for its Abbreviated New Drug Application for Diazepam Injection USP, 10 mg/2 mL (5 mg/mL), Single-Dose Prefilled Syringes.
The U.S. FDA has approved Lupin's Diazepam Injection USP, 10 mg/2 mL (5 mg/mL), Single-Dose Prefilled Syringes as bioequivalent to the reference listed drug (RLD) Valium® Injection 10 mg/2 mL (5 mg/mL) of Hoffman-LaRoche, Inc. and is indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety.
Diazepam Injection USP, 10 mg/2 mL (5 mg/mL), Single-Dose Prefilled Syringes had estimated annual sales of USD 77.9 million in the U.S. (IQVIA MAT May 2026).